尿细胞角蛋白19在膀胱移行细胞癌术后监测中的应用

Evaluation of urinary CK19 during the postoperative follow-up periods of bladder cancer

目的 评价尿细胞角蛋白19片段(CK19,又称CYFRA2 1 1)在膀胱移行细胞癌(BTCC)术后监测中的作用。方法 对67例保留膀胱的BTCC术后患者定期行膀胱镜检查发现2 1例复发,采用电化学发光免疫分析(ECLIA)技术测定复发组(2 1例)、未复发组(4 6例)和正常对照组(2 4例)的尿CKl9含量。结果 复发组尿CKl9的平均值为(19.60±18.5 7) μg/L ,明显高于未复发组(2 .3 3±1.64 ) μg/L和正常对照组(1.82±0 .83 ) μg/L。复发组与未复发组及正常对照组比较,差异有统计学意义(P <0 .0 1)。尿CKl9对BTCC复发的敏感性为90 .5 % ,特异性为76.0 %。结论 尿CKl9是监测BTCC术后复发较为敏感。

Objective To evaluate the value of urinarycytokeratin 19 during the follow-up periods of bladder transitional cell carcinoma (BTCC).Methods Sixty-seven BTCC patients who were under surveillance after reserved bladder operations were recruited from February 2000 to October 2004.Twenty-one recurrent patients were diagnosed by cystoscopy.ECLIA was used to measure the contents of urine CK19 in the patients and healthy volunteers.Results The contents of urine CK 19 in the recurrent patients (19.60± 18.57) μg/L was significently higher than that in the non-recurrent patients (2.33± 1.64) μg/L and the healthy volunteers (1.82± 0.83) μg/L.The sensitivity for detection of recurrent BTCC was 90.5%, and the specificity was 76.0%.Conclusion Urine CK19 is a sensitive,special,rapid and non-invasive parameter for monitoring the relapse of BTCC.